A nine–year-old female neutered Somali cat presented with a one-month history of weight loss and inappetance. Thoracic radiographs revealed an extensive cranial mediastinal mass, and fine needle aspirate cytology and core needle biopsies were initially suggestive of a thymoma. The mass was excised via a mid-ine sternotomy and partial pericardectomy. Clinical signs recurred four weeks postsurgery and investigations revealed recurrence of a mediastinal mass, pleural effusion and an additional small mass cranial to the right kidney. Histopathological examination and immunohistochemistry of the previously resected mass prompted a revised diagnosis of histiocytic sarcoma (HS) with abdominal metastasis. The cat was treated with doxorubicin and lomustine but did not respond well and was euthanased two months later. HS is an uncommon neoplasm in cats with only two cases of mediastinal involvement reported in the literature. This case underlines the importance of immunohistochemistry in the evaluation of mediastinal masses.
Background: Metastatic disease is frequently present at the time of diagnosis of canine thyroid carcinoma; however, utilisation of computed tomography (CT) alone for staging pre‐treatment has been rarely reported in the veterinary literature. Methods: The aims of this retrospective study were to stage affected dogs using CT findings of the cervical and thoracic regions, combined with histopathology/cytology results, in order to assess whether metastatic disease/WHO staging was of prognostic significance. Results: Fifty‐eight dogs were included in the study. Classification of cases into WHO stages I, II, III and IV were 10%, 50%, 9% and 31%, respectively. No statistically significant effect of WHO stage classification on overall survival/follow‐up time was found (P = .576). Surgery resulted in a statistically significant increase in overall survival/follow‐up time (P < .01). There was no statistically significant effect on overall survival/follow‐up time in dogs that received medical therapy, either as sole therapy or as an adjunctive post‐surgery (P = .198). Conclusion: In summary, this study documents the metastatic rate of canine thyroid carcinoma using CT for staging pre‐treatment. Staging utilising CT revealed a higher distant metastatic rate in dogs with thyroid carcinoma when compared to historical studies using different imaging techniques. As long‐term outcomes are possible for cases with advanced disease, surgical intervention could still be considered.
Background After a strong epidemiological link to diet was established in an outbreak of pancytopenia in cats in spring 2021 in the United Kingdom, 3 dry diets were recalled. Concentrations of the hemato‐ and myelotoxic mycotoxins T‐2, HT‐2 and diacetoxyscirpenol (DAS) greater than the European Commission guidance for dry cat foods were detected in the recalled diets. Objectives To describe clinical and clinicopathological findings in cats diagnosed with suspected diet induced pancytopenia. Animals Fifty cats presenting with pancytopenia after exposure to a recalled diet. Methods Multicenter retrospective case series study. Cats with known exposure to 1 of the recalled diets were included if presented with bi‐ or pancytopenia and underwent bone marrow examination. Results Case fatality rate was 78%. Bone marrow aspirates and biopsy examination results were available in 23 cats; 19 cats had a bone marrow aspirate, and 8 cats had a biopsy core, available for examination. Bone marrow hypo to aplasia—often affecting all cell lines—was the main feature in all 31 available core specimens. A disproportionately pronounced effect on myeloid and megakaryocytic cells was observed in 19 cats. Myelofibrosis or bone marrow necrosis was not a feature. Conclusion and Clinical Importance Mycotoxin induced pancytopenia should be considered as differential diagnosis in otherwise healthy cats presenting with bi‐ or pancytopenia and bone marrow hypo‐ to aplasia.
No abstract
The tolerability and cost of multi-agent chemotherapy protocol can be an impediment for some patients with lymphoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.